ストックスクリーナーアプリを入手
34.47
1.45%
0.5636
前日終値:
$33.91
開ける：
$34
24時間の取引高:
34,937
Relative Volume:
0.21
時価総額：
$932.56M
収益：
-
当期純損益:
$-69.47M
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
$-73.92M
1週間 パフォーマンス:
+1.39%
1か月 パフォーマンス:
+26.52%
6か月 パフォーマンス:
+84.55%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$33.10
$34.55
1週間の範囲:
$31.59
$35.40
52週間の値動き範囲:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
名前
Lenz Therapeutics Inc
セクター
電話
858-925-7000
住所
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
LENZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LENZ | 34.40 | 932.56M | 0 | -69.47M | -73.92M | 0.00 |
| VRTX | 447.31 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.17 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.86 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.13 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lenz Therapeutics Inc (LENZ) 最新ニュース
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - MSN
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3%Here's Why - MarketBeat
TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics I - GuruFocus.com
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - The Malaysian Reserve
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year HighWhat's Next? - MarketBeat
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences | LENZ Stock News - StockTitan
Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings - MarketBeat
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - Yahoo Finance
FY2024 EPS Estimate for LENZ Therapeutics Boosted by Analyst - MarketBeat
William Blair Has Bullish Outlook for LENZ FY2024 Earnings - MarketBeat
Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks
LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com UK
Form 424B3 LENZ Therapeutics, Inc. - StreetInsider.com
LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Employ Inc. Announces Promotion of Stephanie Manzelli to Chief Human Resources Officer - The Manila Times
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Registration Open for CME/CE-Accredited Free Event Nov 7 - InvisionMag
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 - The Manila Times
LENZ Therapeutics Insider Buyers See Boost After Market Cap Rose US$97m - Simply Wall St
Corxel and LENZ share positive results from Phase III China trial - The Pharma Letter
LENZ reports positive Chinese study data for far-sightedness drug - MSN
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships - AOL
Wescott Financial Advisory Group LLC Acquires 2,154 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 - ForexTV.com
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial - The Bakersfield Californian
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Price Target from Analysts - MarketBeat
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance
Mcf Energy Ltd (MCF-X) QuotePress Release - The Globe and Mail
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - Marketscreener.com
Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga
One new option listing and ten option delistings on October 21st - TipRanks
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia - Marketscreener.com
Behind the Bell: LENZ Therapeutics - Nasdaq
FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs - MarketBeat
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc. - Yahoo Finance
Lenz Co. stock soars to 52-week high, hits $26.18 By Investing.com - Investing.com Canada
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Yahoo Finance
TJX Companies (TJX-N) QuotePress Release - The Globe and Mail
Dimensional Fund Advisors LP Increases Holdings in Koss Co. (NASDAQ:KOSS) - Defense World
Creative Planning Buys 296 Shares of PVH Corp. (NYSE:PVH) - Defense World
Lenz Therapeutics Inc (LENZ) 財務データ
収益
当期純利益
現金流量
EPS
Lenz Therapeutics Inc (LENZ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 21 '24 |
Buy |
15.03 |
998,009 |
15,000,075 |
3,319,339 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):